12:00 AM
 | 
Jul 14, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pyridorin pyridoxamine: Phase III started

NephroGenex began the double-blind, placebo-controlled, international Phase III PYR-311 trial to evaluate 300 mg oral Pyridorin twice daily until ESRD or death occurs in about 600 patients with nephropathy due to Type II diabetes. PYR-311 is the first of 2 identical trials NephroGenex is conducting under its...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >